ClinConnect ClinConnect Logo
Search / Trial NCT05911412

Development of the Neuroimaging Biomarker-based Prediction Model of Anxiety-related Disorders: Effect of Mindfulness-based Cognitive Therapy Using Neuroscience on the Brain

Launched by CHA UNIVERSITY · Jun 9, 2023

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Mindfulness Based Cognitive Therapy Mri Neuroscience

ClinConnect Summary

This clinical trial is investigating a new type of therapy called mindfulness-based cognitive therapy using neuroscience (NMBCT) to help reduce symptoms of anxiety and depression in adults. The study will last for 8 weeks and aims to see how this therapy might change brain activity and structure, as well as help participants feel better overall. It is important to note that the trial is not currently recruiting participants.

To be eligible for this study, you need to be over 19 years old and have mild to moderate levels of anxiety or depression. Specifically, your scores on certain questionnaires must fall within specific ranges. Additionally, the study is looking for individuals who are right-handed, have normal vision, and do not have a family history of psychiatric illnesses. Participants can expect to engage in therapy sessions and may also undergo brain imaging to assess changes throughout the trial. It's important to remember that those currently taking certain medications or with specific medical histories may not be able to participate.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • over 19 years of age
  • a Beck Depression Inventory score of more than 5 but less than 20 points
  • a Beck Anxiety Inventory score of more than 5 but less than 25 points
  • A person who has been sufficiently explained and understood the contents of clinical trials, and maintains the ability to make a free-will decision
  • Those with normal or normal corrected vision
  • Those without claustrophobic symptoms
  • Right-handed person
  • Those who do not have a family history of psychiatric disease in the first family (parents, children, siblings)
  • Exclusion Criteria:
  • Currently taking psychoactive drugs
  • Those with a history of neurological disease, head trauma with loss of consciousness, or mental retardation (IQ \<70)
  • A person who currently requires hospitalization due to a serious physical illness or who has not passed 6 months since discharge
  • Pregnant and lactating women
  • A person who is judged to be at risk of serious suicide or violent behavior in a mental status examination
  • A person who is judged to have severe symptoms or significant decline in reality testing and judgment through a mental status examination by a psychiatrist
  • Foreigners
  • Those who are illiterate in Korean
  • Those who have previously received mindfulness-based cognitive therapy
  • If the researcher judges that the researcher is unsuitable for participation in clinical trials due to other reasons

About Cha University

CHA University is a leading research institution dedicated to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, CHA University engages in cutting-edge research across various fields, including oncology, cardiology, and regenerative medicine. The university fosters a dynamic environment for clinical research, driven by a commitment to ethical standards and patient safety, ensuring that all trials are conducted with the highest level of scientific rigor. Through its extensive network of healthcare professionals and state-of-the-art facilities, CHA University aims to contribute significantly to the development of new therapies and enhance the understanding of complex medical conditions.

Locations

Patients applied

0 patients applied

Trial Officials

Sang-Hyuk Lee, MD., PhD

Principal Investigator

Professor at Bundang CHA medical center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported